AI-generated analysis. Always verify with the original filing.
Azenta UK Ltd., a wholly owned subsidiary of Azenta, Inc., entered into a Share Purchase Agreement on March 4, 2026, to acquire all issued and outstanding share capital of UK Biocentre Limited for total consideration of GBP 20.5 million net of cash, inclusive of up to GBP 1.8 million in contingent consideration. UK Biocentre will serve as a European-wide hub for Azenta’s Sample Repository Services business and continue operating under its name.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into Material Definitive Agreement. On March 4, 2026, Azenta UK Ltd., a wholly owned subsidiary of Azenta, Inc. (“Azenta” or the “Company”) entered into a
, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, n
. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 2.1 Share Purchase Agreement dated March 4, 2026 between Azenta UK Ltd. and UK Biocent
Acquisition / Disposition
Material Agreement